Orchid Pharma share price
NSE: ORCHPHARMABSE: 524372Pharmaceuticals & BiotechnologySmall Cap
Orchid Pharma Limited · Formerly Orchid Chemicals & Pharmaceuticals · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 1993 on BSE, Jul 2010 on NSE
Last close ₹835.35up ₹17.00 (2.08%)BSE ₹835.05
Share price at the NSE close on 27 Oct 2026. Previous close ₹818.35.
27 Oct: open ₹818.35, high ₹841.90, low ₹818.35
52-week range of traded prices to 27 Oct 2026
₹480.00Low, 30 Mar 2026₹1,143.50High, 22 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹5,003 Cr919th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 0.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.19
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 54,56657.3% delivered
About Orchid Pharma
Orchid Pharma Limited is an Indian drug maker focused on anti-infectives (medicines that fight infections), including cephalosporin antibiotics.12 It is building a platform meant to run from fermentation and key starting materials through active pharmaceutical ingredients (APIs, the active substance in a medicine) to finished sterile injectable medicines.2 Its registered office is at Alathur, Tamil Nadu, and its corporate office in Gurugram, Haryana; it sells in India and abroad.34
The company reports a single business segment, pharmaceuticals.5 Its Antimicrobial Solutions division works with hospitals and infection control committees on when advanced antibiotics should and should not be used.6
It has manufacturing sites at Alathur in Chennai, Manesar in Haryana and Keshwana in Rajasthan, and an upcoming site in Jammu.1 It exports to more than 40 countries.4
The company was founded in Chennai in 1992 as an export-oriented unit.1 Under an insolvency resolution plan approved by the National Company Law Tribunal, it became a subsidiary of Dhanuka Laboratories Limited on 31 Mar 2020.7 Dhanuka Laboratories was merged into the company under a scheme sanctioned by the National Company Law Tribunal, Chennai, on 5 Jun 2026, effective 10 Jul 2026, with 1 Apr 2024 as the appointed date (the date from which the accounts combine).7 It is part of the Dhanuka Group, whose founder chairman, Ram Gopal Agarwal, chairs the company; Manish Dhanuka is managing director.83 Its promoters include Triveni Trust, with 32.62% of the shares at 31 Mar 2026, and Manish Dhanuka, with 10.94%, counting shares since allotted under the merger.910
Orchid Pharma key points
Results
- Consolidated revenue from operations was ₹1,232.78 crore in the year to Mar 2026, against ₹1,397.61 crore a year earlier; profit after tax was ₹9.96 crore, against ₹135.07 crore. Both years are restated to include Dhanuka Laboratories.11
- EBITDA (earnings before interest, tax, depreciation and amortisation) was ₹94.27 crore in the year to Mar 2026, against ₹187.14 crore a year earlier.12
- On a combined basis, revenue from operations in the quarter to Jun 2026 was ₹304 crore, against ₹263 crore a year earlier, and EBITDA was ₹25 crore, against ₹10 crore; the company said it returned to profit in the quarter.131415
- Combined gross margin (revenue left after the cost of materials, as a share of revenue) was about 32% in the year to Mar 2026, against about 36% a year earlier, and about 33% in the quarter to Jun 2026, against about 30%.1613
Market position
- The company says it runs 1 of 3 sites in the world approved by the US Food and Drug Administration (FDA) to make sterile cephalosporins.12
- The company said volumes and prices in a number of its important products and markets fell 15% to 20%, depending on the product, in the year to Mar 2026, as global cephalosporin markets carried excess capacity.1718
Enmetazobactam
- Enmetazobactam, invented in the company's own laboratories, is India's first indigenously discovered new chemical entity (a new drug molecule) to receive US FDA approval. It is sold as EXBLIFEP abroad and as Orblicef in India.19
- The company acquired the assets of Allecra Therapeutics SAS, France, on 1 Aug 2025 and of Allecra Therapeutics GmbH, Germany, on 29 Oct 2025, and now owns 100% of enmetazobactam worldwide.20
- In Western Europe it is sold by partner Advanz Pharma, which has launched it in Spain, Italy, Germany, France and the UK; registration in South Africa is complete. In India the company makes it, supplies Cipla and sells Orblicef.212223
- On its earnings call of 21 Aug 2026, the company said the estimated 10-year value of its licensing arrangement in Russia is about $178 million, a long-term value, not current period revenue, depending on registration, launch and market development.24
Expansion and capital spending
- The company stated in its annual report for the year to Mar 2026 that its Jammu plant for 7-ACA, the starting material for most cephalosporins, which India imports entirely, is progressing towards commercial operations in the first quarter of calendar 2027.19
- On its earnings call of 21 Aug 2026, the company said capital spending for the 7-ACA project is ₹750 crore and for the cefiderocol project $20 million to $25 million, and that it expects to complete both projects in the year to Mar 2027.25
- The Global Antibiotic Research and Development Partnership selected the company to make cefiderocol, an antibiotic for resistant infections, and supply it across 135 countries; as of 8 Sep 2026 the project was progressing towards commissioning.26
What the company expects
- The company stated in its annual report for the year to Mar 2026 that the combined company targets revenue of ₹1,400 to 1,500 crore and EBITDA of ₹200 to 250 crore, without giving a year for the target.27
- On its earnings call of 21 Aug 2026, the company said it plans to take the new Jammu plant to 80% to 100% use by the end of its first year, and over the long term to use 80% of output itself and sell 20%.28
- On its earnings call of 21 Aug 2026, the company said it is at an advanced stage of talks with partners for enmetazobactam in South America, Mexico, the Philippines, Thailand, Morocco and Australia.23
Recent events
- Dhanuka Laboratories' shareholders received 161 company shares for every 5 they held; the 4,45,86,052 new shares were listed on the National Stock Exchange and BSE on 23 Sep 2026.2930
- On 1 Apr 2026, the credit rating agency CARE Ratings (which grades a borrower's ability to repay) downgraded the company's long-term bank facilities to CARE BBB+ from CARE A-, with a stable outlook.31
Litigation and regulatory matters
- On 9 Jun 2026, the company received an order from the Additional Commissioner of Central Tax, Chennai Outer Commissionerate, confirming a demand to recover a refund of ₹1,67,07,937 plus interest, for a period before its insolvency process.3233
- In its filing of 11 Jun 2026, the company said it intends to appeal that tax order and expects no material impact; its documents give no later step.33
- On 2 Apr 2026, the National Company Law Tribunal, Chennai, dismissed an application by DBS Bank (formerly Lakshmi Vilas Bank) claiming lease dues for the period of the company's insolvency process; the company's documents give no later step.34
Last updated
All 34 sources, each with its page
- 1. Annual report, 8 Sep 2026, page 15
- 2. Annual report, 8 Sep 2026, page 12
- 3. Investor presentation, 20 Aug 2026, page 1
- 4. Annual report, 8 Sep 2026, page 294
- 5. Annual report, 8 Sep 2026, page 328
- 6. Annual report, 8 Sep 2026, page 11
- 7. Annual report, 8 Sep 2026, page 294
- 8. Annual report, 8 Sep 2026, page 7
- 9. Annual report, 8 Sep 2026, page 240
- 10. Annual report, 8 Sep 2026, page 240
- 11. Annual report, 8 Sep 2026, page 10
- 12. Annual report, 8 Sep 2026, page 15
- 13. Earnings call, 21 Aug 2026, page 4
- 14. Earnings call, 21 Aug 2026, page 3
- 15. Annual report, 8 Sep 2026, page 12
- 16. Earnings call, 21 Aug 2026, page 3
- 17. Earnings call, 21 Aug 2026, page 3
- 18. Annual report, 8 Sep 2026, page 10
- 19. Annual report, 8 Sep 2026, page 11
- 20. Annual report, 8 Sep 2026, page 312
- 21. Earnings call, 21 Aug 2026, page 11
- 22. Earnings call, 21 Aug 2026, page 7
- 23. Earnings call, 21 Aug 2026, page 4
- 24. Earnings call, 21 Aug 2026, page 4
- 25. Earnings call, 21 Aug 2026, page 8
- 26. Annual report, 8 Sep 2026, page 11
- 27. Annual report, 8 Sep 2026, page 15
- 28. Earnings call, 21 Aug 2026, page 6
- 29. Exchange filing, 10 Jul 2026, page 1
- 30. Exchange filing, 23 Sep 2026, page 1
- 31. Exchange filing, 2 Apr 2026, page 2
- 32. Exchange filing, 11 Jun 2026, page 2
- 33. Exchange filing, 11 Jun 2026, page 1
- 34. Exchange filing, 11 Apr 2026, page 1
Results
Consolidated; ₹ crore.Orchid Pharma quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +26.2%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- –
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹304 Crdown 17.42%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹3.22 Crdown 87.52%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 1.1%
Revenue by quarter
Net profit by quarter, a loss in red
- Net profit
- Loss
A loss in 2 of the 8 quarters shown
The quarters either side of a change of basis do not compare. From the quarter to Mar 2026, the company's revenue for the year to Mar 2026, ₹1,233 Cr, differs from its quarters added, ₹942 Cr.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 223 | 217 | 237 | 173 | 194 | 207 | 368 | 304 |
| Net profit | 27 | 21 | 22 | 15 | −6 | −13 | 26 | 3 |
| Net margin | 12.2% | 9.6% | 9.4% | 8.7% | −3.0% | −6.1% | 7.0% | 1.1% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026
- Revenue
- ₹1,233 Cr
- Net profit
- ₹9.96 Cr
- Net margin
- 0.8%
Revenue by year
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 5 of the 10 years shown
The years either side of a change of basis do not compare. From the year to Mar 2021, the company reports a discontinued business. From the year to Mar 2026, the company's revenue for that year, ₹1,233 Cr, differs from its quarters added, ₹942 Cr.
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 807 | 688what Revenue, Mar 2018, includes. This period's revenue includes excise duty of ₹4.83 crore, a tax on the goods the company makes that it collects and pays to the government. | 600 | 508 | 450 | 560 | 666 | 819 | 922 | 1,233 |
| Net profit | −490 | −353 | 69 | −131 | −117 | −2 | 46 | 92 | 100 | 10 |
| Net margin | −60.7% | −51.3% | 11.6% | −25.8% | – | – | – | 11.2% | 10.8% | 0.8% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share. Net margin is left blank for Mar 2021, Mar 2022 and Mar 2023: the profit includes the result of a business the company has discontinued, which the revenue does not, so the two make no margin.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −37.8% | −91.6% | +635.8% | 0.0% |
| 3 years | +8.0% | −47.3% | +104.9% | 0.0% |
| 5 years | −27.5% | – | – | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record. Earnings growth over 1 and 3 years includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the years to Mar 2023 and Mar 2026.
Mutual fund holdings
26 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 2 of the 8 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.All 26 funds holding Orchid Pharma
- AddedAdded. Funds that held more shares than at the end of the month before.
- 4
- CutCut. Funds that held fewer shares than at the end of the month before.
- 4
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 18
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 1
| Fund | |||
|---|---|---|---|
 quant Small Cap Fundquant Mutual Fund | 34,65,947 | 0.97% | ₹345.6 Cr |
 UTI Value FundUTI Mutual Fund | 11,88,926 | 1.31% | ₹118.5 Cr |
 Invesco India Contra FundInvesco Mutual Fund | 9,90,763 | 0.51% | ₹98.8 Cr |
 Kotak Multi Asset Allocation FundKotak Mahindra Mutual Fund | 9,42,962 | 0.62% | ₹94.0 Cr |
| UTI Small Cap FundUTI Mutual Fund | 5,09,966 | 0.97% | ₹50.8 Cr |
| Kotak Special Opportunities FundKotak Mahindra Mutual Fund | 4,87,811 | 2.53% | ₹48.6 Cr |
| Invesco India Small Cap FundInvesco Mutual Fund | 4,55,183 | 0.28% | ₹45.4 Cr |
 Bandhan Small Cap FundBandhan Mutual Fund | 4,54,372 | 0.13% | ₹45.3 Cr |
| Kotak Consumption FundKotak Mahindra Mutual Fund | 2,86,000 | 1.72% | ₹28.5 Cr |
| Kotak Multi Cap FundKotak Mahindra Mutual Fund | 2,64,308 | 0.09% | ₹26.4 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 28 Oct 2025.Orchid Pharma insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Promoters and promoter group: no market trade
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Orchid Pharma competitors and peers
Pharmaceuticals, 216 listed companies, priced on 27 Oct 2026. The table lists the 8 companies closest to Orchid Pharma in market cap.Healthcare companies
Orchid Pharma is not on the chart: it has no P/E or return on equity today
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Senores PharmaceuticalsSENORES | 6,038 | 45.94 | 6.47 | – | – | 15.3% | 13.1% | 0.00% |
 Sun Pharma Advanced Research CompanySPARC | 5,817 | 3.67 | 4.34 | +2,855.8% | – | 118.4% | 84.8% | 0.00% |
 FDCFDC | 5,760 | 18.39 | 2.16 | +10.2% | +39.0% | 12.3% | 11.5% | 1.41% |
 IOL Chemicals and PharmaceuticalsIOLCP | 5,265 | 31.32 | 2.93 | +18.6% | +60.1% | 9.6% | 11.8% | 0.56% |
 RPG Life SciencesRPGLIFE | 4,691 | 39.27 | 7.75 | +11.8% | −34.6% | 21.0% | 21.3% | 0.85% |
 Gujarat Themis BiosynGUJTHEM | 4,589 | 94.25 | – | +17.5% | +9.2% | 18.2% | 15.1% | 0.19% |
 Novartis IndiaNOVARTIND | 4,562 | 46.66 | 5.58 | +5.4% | −4.9% | 12.2% | 12.2% | 0.00% |
 Zota Health CareZOTA | 4,433 | – | 6.39 | +78.9% | – | −22.5% | −12.8% | 0.08% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Orchid Pharma announcements
Oct 2026
20 Oct · Board meeting
15 Oct · Board meeting
Sep 2026
Orchid Pharma share price by year
Each calendar year to 2025.Orchid Pharma share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 758.95 | −58.0% | 1,982.50 | 628.75 |
| 2024 | 1,807.05 | +153.6% | 1,829.90 | 709.60 |
| 2023 | 712.50 | +95.7% | 734.70 | 334.20 |
| 2022 | 364.05 | −7.8% | 445.75 | 269.30 |
| 2021 | 394.90 | +220.4% | 2,527.90 | 129.40 |
| 2020 | 123.25 | – | 123.25 | 18.00 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2020 is from its first session, 3 Nov 2020.
Recent sessions
The 9 trading days to 26 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 26 Oct 2026 | 834.45 | 850.25 | 810.55 | 818.35 | 829.56 | 86,013 | 44.4% |
| 23 Oct 2026 | 879.95 | 880.25 | 809.05 | 823.30 | 824.40 | 1,70,480 | 53.5% |
| 22 Oct 2026 | 877.05 | 885.10 | 860.75 | 875.55 | 873.34 | 52,511 | 39.8% |
| 21 Oct 2026 | 885.10 | 911.90 | 872.50 | 886.90 | 892.59 | 1,08,837 | 40.5% |
| 19 Oct 2026 | 911.25 | 941.50 | 875.00 | 893.50 | 906.80 | 1,27,390 | 27.1% |
| 16 Oct 2026 | 935.00 | 938.95 | 896.00 | 911.25 | 908.64 | 1,04,768 | 50.3% |
| 15 Oct 2026 | 945.25 | 950.25 | 925.00 | 928.05 | 937.54 | 42,563 | 47.4% |
| 14 Oct 2026 | 959.95 | 968.30 | 940.00 | 945.25 | 954.89 | 35,546 | 46.1% |
| 13 Oct 2026 | 975.10 | 981.75 | 947.00 | 959.95 | 961.61 | 50,365 | 49.5% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Offer for sale history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 3 Nov 2020 | Price move | – | Between two trading sessions the price fell 47% or more, or rose 90% or more. No corporate action is on record. Earlier prices are not shown. |
| 17 Mar 2008 | Price move | – | Between two trading sessions the price moved by a fifth or more. The Nifty 500 moved 5% or more the same way over the same sessions. Not adjusted for. |
Where an event has no factor that can be worked out, the chart leaves out the closes before it. Any other event is noted and not adjusted for.
Company details
- NSE symbol
- ORCHPHARMA
- BSE code
- 524372
- ISIN
- INE191A01027
- Industry
- Pharmaceuticals & Biotechnology
- Former symbols
- ORCHIDPHAR, ORCHIDCHEM, ORCHIDCHEM
- Website
- www.orchidpharma.com
- CIN
- L24222TN1992PLC022994
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1992
- Registered office
- 121-128, 128A-133, 138-151, 159-164, SIDCO Industrial Estate, Alathur, Chengalpettu 603110, Tamil Nadu
- Share registrar
- Abhipra Capital Ltd
- Keeps the register of shareholders and handles transfers and dividend payments